New, two-chip, single-cell optofluidic system ideal for small- to mid-sized biopharma & CDMOs/CROs to affordably gain access to the Beacon ® technology and cell line development-specific applications ...

Join us as we reveal the revolutionary capabilities of Bruker Cellular Analysis' Beacon Optofluidic system. The Beacon platform provides a complete picture of single cell function through real-time ...

The revolution in life science research aims to understand how single cells work, which is crucial for developing new therapies. Traditional methods like FACS and scRNASeq give only a partial view of ...

Beacon Quest designed with affordable two-chip optofluidic system to accelerate the pace of scientific discovery across academic, non-profit, and government research including comprehensive single T ...

Bruker Corporation today announced the launch of the Beacon Discovery ™ Optofluidic System at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. This new Beacon benchtop ...

Successfully producing large quantities of biotherapeutics, including monoclonal antibodies and recombinant protein products, depends on robust and reliable cell line development (CLD). Issues that ...

In the last few years, multispecific antibodies, such as bispecific, trispecific, and tetraspecific antibodies, have become the breakthrough stars in antibody therapeutics. Compared with conventional ...

New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules SEATTLE--(BUSINESS WIRE)--As drug ...

Building on Bruker’s proprietary Opto-Electrical Positioning (OEP) technology and scalable OptoSelect™ microfluidic chips, Beacon Discovery complements the floor-standing premium Beacon® platforms.